您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Telmisartan-d3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Telmisartan-d3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Telmisartan-d3图片
CAS NO:1189889-44-8
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
An internal standard for the quantification of telmisartan
Cas No.1189889-44-8
别名替米沙坦 d3
Canonical SMILESCC1=CC(C2=NC3=C(C=CC=C3)N2C([2H])([2H])[2H])=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5
分子式C33H27D3N4O2
分子量517.6
溶解度DMF: Soluble,DMSO: Soluble
储存条件Store at 2°C to 8°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Telmisartan-d3is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT1(Ki= 3.7 nM).1It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone .2Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.3,4,5

1.Wienen, W., Hauel, N., Van Meel, J.C.A., et al.Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br. J. Pharmacol.110245-252(1993) 2.Benson, S.C., Pershadsingh, H.A., Ho, C.I., et al.Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension43(5)993-1002(2004) 3.McClellan, K.J., and Markham, A.TelmisartanDrugs56(6)1039-1044(1998) 4.Jugdutt, B.I.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyClin. Interv. Aging5403-416(2010) 5.Schmieder, R.E., Bakris, G., and Weir, M.R.Telmisartan in incipient and overt diabetic renal diseaseJ.Nephrol.24(3)263-273(2011)